Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(1.17) by 24.79 percent. This is a 82.5 percent decrease over losses of $(0.80) per share from the same period last year.